Share on StockTwits

Sangamo Biosciences (NASDAQ:SGMO) CEO Edward O. Lanphier II sold 25,000 shares of Sangamo Biosciences stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $13.95, for a total transaction of $348,750.00. Following the sale, the chief executive officer now directly owns 295,000 shares of the company’s stock, valued at approximately $4,115,250. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Sangamo Biosciences (NASDAQ:SGMO) remained flat at $14.01 during trading on Friday. The stock had a trading volume of 735,330 shares. Sangamo Biosciences has a one year low of $8.93 and a one year high of $24.69. The stock’s 50-day moving average is $13.51 and its 200-day moving average is $15.93. The company’s market cap is $955.0 million.

Sangamo Biosciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. The company had revenue of $10.38 million for the quarter, compared to the consensus estimate of $7.84 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 50.4% on a year-over-year basis. On average, analysts predict that Sangamo Biosciences will post $-0.26 earnings per share for the current fiscal year.

Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Sangamo Biosciences in a research note on Friday, August 1st. They set an “overweight” rating and a $22.00 price target on the stock.

Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.